Ferrostatin-1-loaded polymeric micelles with IMTP modification and ROS responsiveness alleviate post-resuscitation myocardial dysfunction by inhibiting ferroptosis
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2026.179357 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Xiaoyu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Second Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui Province, …. Hauptthemen laut MEDLINE: Ferroptosis, Reactive Oxygen Species, Phenylenediamines, Cyclohexylamines. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Anhui Science and Technology Department, National Natural Science Foundation of China, Anhui Provincial Natural Science Foundation.
Themen: Reanimation
Abstract (Originalsprache)
Post-resuscitation myocardial dysfunction (PRMD) is a leading cause of early mortality following cardiac arrest (CA), and ferroptosis has been implicated as a key mechanism. However, effective ferroptosis-targeted therapies are limited. Here, we developed ischemic myocardium-targeting peptide (IMTP)-modified, reactive oxygen species (ROS)-responsive polymeric micelles (Fer-1-NP) by encapsulating ferrostatin-1 (Fer-1) in poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) micelles and incorporating diselenide (Se-Se) bonds for ROS-triggered release and IMTP modification to promote cardiac localization. Fer-1-NP exhibited a uniform nanoscale morphology, high drug-loading efficiency, ROS-responsive release, and intrinsic ROS-scavenging activity. In vitro, Fer-1-NP protected H9c2 cardiomyocytes from hypoxia/reoxygenation injury by improving cell viability, restoring mitochondrial membrane potential, and reducing lipid peroxidation. In a rat CA model, Fer-1-NP exhibited increased cardiac fluorescence intensity, improved myocardial localization, enhanced left ventricular ejection fraction and mean arterial pressure, reduced serum cTnI and CK-MB levels, and preserved myocardial architecture compared with free Fer-1. Mechanistically, Fer-1-NP attenuated ferroptosis-associated changes by reducing myocardial Fe2+, 4-HNE, and MDA levels, restoring GSH levels, and regulating GPX4, ACSL4, SLC7A11, and FTH1 expression. In vivo imaging demonstrated the preferential cardiac accumulation of IMTP-modified micelles. These findings suggest that IMTP-functionalized, ROS-responsive Fer-1-NP provide cardioprotection against PRMD through modulation of ferroptosis-associated injury, representing a promising therapeutic strategy after cardiac arrest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui Province, 230601, China; Laboratory of Cardiopulmonary Resuscitation and Critica…
Förderung
- Anhui Science and Technology Department
- National Natural Science Foundation of China
- Anhui Provincial Natural Science Foundation
Zitieren
APA
Zhang, X., Shi, W., Ji, Y., Zhu, S., Guo, H., Cao, S., Hua, T., & Yang, M. (2026). Ferrostatin-1-loaded polymeric micelles with IMTP modification and ROS responsiveness alleviate post-resuscitation myocardial dysfunction by inhibiting ferroptosis. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.179357
Vancouver
Zhang X, Shi W, Ji Y, Zhu S, Guo H, Cao S, et al. Ferrostatin-1-loaded polymeric micelles with IMTP modification and ROS responsiveness alleviate post-resuscitation myocardial dysfunction by inhibiting ferroptosis. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.179357
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaoyu and Shi, Wei and Ji, Yu and Zhu, Shuaijie and Guo, Heng and Cao, Susu and Hua, Tianfeng and Yang, Min},
title = {Ferrostatin-1-loaded polymeric micelles with IMTP modification and ROS responsiveness alleviate post-resuscitation myocardial dysfunction by inhibiting ferroptosis},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2026.179357}
}
EUVIMED